Complex generic product sponsors seem to have a better handle on the purpose of the US Food and Drug Administration's pre-ANDA meeting program but still are struggling with the requirements.
Data through the first three quarters of fiscal year 2019 suggest that sponsors are seeing fewer meeting requests denied because they were inappropriate, but more because the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?